Recombinant MVA vaccines: Dispelling the myths

Vaccine

Volumn 31, Issue 39, 2013, Pages 4247-4251

  Cottingham, Matthew G ^a   Carroll, Miles W ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Genetic vaccine; HIV; Malaria; Modified vaccinia virus Ankara (MVA); Poxvirus; Recombinant; Tuberculosis; Vaccine; Vaccinia virus; Vector

Indexed keywords

ADENOVIRUS VECTOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; RECOMBINANT VACCINE; SMALLPOX VACCINE;

ARTICLE; CELLULAR IMMUNITY; DRUG MANUFACTURE; FOWLPOX VIRUS; GENETIC STABILITY; HELA CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; INOCULATION; PRIORITY JOURNAL; TRANSGENE; VACCINATION; VACCINIA VIRUS; VIRUS GENOME; VIRUS REPLICATION;

GENETIC VACCINE; HIV; MALARIA; MODIFIED VACCINIA VIRUS ANKARA (MVA); POXVIRUS; RECOMBINANT; TUBERCULOSIS; VACCINE; VACCINIA VIRUS; VECTOR;

ANIMALS; GENETIC VECTORS; HUMANS; NEOPLASMS; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84882872270     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.021     Document Type: Article

References (69)

1. Smith G.L., Murphy B.R., Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A 1983, 80(December (23)):7155-7159.
2. Smith G.L., Mackett M., Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 1983, 302(April (5908)):490-495.
3. Panicali D., Davis S.W., Weinberg R.L., Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 1983, 80(September (17)):5364-5368.
4. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996, 397:7-13.
5. Sutter G., Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Current drug targets Infectious disorders 2003, 3(September (3)):263-271.
6. Skinner M.A., Laidlaw S.M., Eldaghayes I., Kaiser P., Cottingham M.G. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 2005, 4(February (1)):63-76.
7. von Krempelhuber A., Vollmar J., Pokorny R., Rapp P., Wulff N., Petzold B., et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010, 28(February (5)):1209-1216.
8. Vaccari M., Poonam P., Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 2010, 9(September (9)):997-1005.
9. Gomez C.E., Najera J.L., Krupa M., Perdiguero B., Esteban M.M.V.A NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011, 11(June (3)):189-217.
10. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 2007, 25(July (30)):5606-5612.
11. Weyer J., Rupprecht C.E., Nel L.H. Poxvirus-vectored vaccines for rabies--a review. Vaccine 2009, 27(November (51)):7198-7201.
12. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., Hill A.V. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011, 23(June (3)):377-382.
13. Mayr A., Stickl H., Muller H.K., Danner K., Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B] 1978, 167(December (5-6)):375-390.
14. Wyatt L.S., Carroll M.W., Czerny C.P., Merchlinsky M., Sisler J.R., Moss B. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 1998, 251(November (2)):334-342.
15. Meisinger-Henschel C., Schmidt M., Lukassen S., Linke B., Krause L., Konietzny S., et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol 2007, 88(December (12)):3249-3259.
16. Whelan K.T., Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS ONE 2009, 4(6):e5934.
17. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40(January (1)):279-290.
18. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52(January (1)):1-7.
19. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4(January (115)):115ra2.
20. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205(March (5)):772-781.
21. Sheehy S.H., Duncan C.J., Elias S.C., Biswas S., Collins K.A., O'Hara G.A., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 2012, 7(2):e31208.
22. Sheehy S.H., Duncan C.J., Elias S.C., Collins K.A., Ewer K.J., Spencer A.J., et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011, 19(December (12)):2269-2276.
23. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012, 4(January (115)):ra1.
24. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372(November (9653)):1894-1905.
25. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(November (9653)):1881-1893.
26. de Souza M.S., Ratto-Kim S., Chuenarom W., Schuetz A., Chantakulkij S., Nuntapinit B., et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012, 188(May (10)):5166-5176.
27. Gilbert S.C., Moorthy V.S., Andrews L., Pathan A.A., McConkey S.J., Vuola J.M., et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006, 24(May (21)):4554-4561.
28. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 2005, 102(March (13)):4836-4841.
29. Gilbert S.C. T-cell-inducing vaccines - what's the future. Immunology 2012, 135(January (1)):19-26.
30. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365(November (20)):1863-1875.
31. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17(July (7)):1055-1065.
32. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244(May (2)):365-396.
33. Suter M., Meisinger-Henschel C., Tzatzaris M., Hulsemann V., Lukassen S., Wulff N.H., et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 2009, 27(December (52)):7442-7450.
34. Cottingham M.G., Gilbert S.C. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. J Virol Methods 2010, 168(September (1/2)):233-236.
35. Mayr A., Hochstein-Mintzel V., Abstammung Stickl H. Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 1975, 3(1):6-14.
36. Qin L., Upton C., Hazes B., Evans D.H. Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine. J Virol 2011, 85(December (24)):13049-13060.
37. Burgers W.A., Shephard E., Monroe J.E., Greenhalgh T., Binder A., Hurter E., et al. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 2008, 24(February (2)):195-206.
38. Wyatt L.S., Belyakov I.M., Earl P.L., Berzofsky J.A., Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008, 372(March (2)):260-272.
39. Cottingham M.G., Carroll F., Morris S.J., Turner A.V., Vaughan A.M., Kapulu M.C., et al. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol Bioeng 2012, 109(March (3)):719-728.
40. Wyatt L.S., Earl P.L., Xiao W., Americo J.L., Cotter C.A., Vogt J., et al. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 2009, 83(July (14)):7176-7184.
41. Timm A., Enzinger C., Felder E., Chaplin P. Genetic stability of recombinant MVA-BN. Vaccine 2006, 24(May (21)):4618-4621.
42. Orubu T., Alharbi N.K., Lambe T., Gilbert S.C., Expression Cottingham M.G. Cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS One 2012, 7(6):e40167.
43. Earl P.L., Hugin A.W., Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol 1990, 64(May (5)):2448-2451.
44. Wyatt L.S., Earl P.L., Vogt J., Eller L.A., Chandran D., Liu J., et al. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 2008, 26(January (4)):486-493.
45. Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996, 14(October (15)):1451-1458.
46. Hopkins R., Bridgeman A., Joseph J., Gilbert S.C., McShane H., Hanke T. Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One 2011, 6(5):e20067.
47. Baur K., Brinkmann K., Schweneker M., Patzold J., Meisinger-Henschel C., Hermann J., et al. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol 2010, 84(September (17)):8743-8752.
48. Goepfert P.A., Elizaga M.L., Sato A., Qin L., Cardinali M., Hay C.M., et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011, 203(March (5)):610-619.
49. Kreijtz J.H., Suzer Y., Bodewes R., Schwantes A., van Amerongen G., Verburgh R.J., et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 2010, 91(November (11)):2745-2752.
50. Amato R.J., Hawkins R.E., Kaufman H.L., Thompson J.A., Tomczak P., Szczylik C., et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010, 16(November (22)):5539-5547.
51. Jordan I., Vos A., Beilfuss S., Neubert A., Breul S., Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27(January (5)):748-756.
52. Jordan I., Northoff S., Thiele M., Hartmann S., Horn D., Howing K., et al. A chemically defined production process for highly attenuated poxviruses. Biologicals 2011, 39(January (1)):50-58.
53. Jordan I., Sandig V. Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses. BMC proceedings 2011, 5(November (Suppl 8)):O1.
54. Brown S.W., Mehtali M. The avian EB66(R) cell line, application to vaccines, and therapeutic protein production. PDA J Pharm Sci Technol 2010, 64(September-October (5)):419-425.
55. Kraus B., von Fircks S., Feigl S., Koch S.M., Fleischanderl D., Terler K., et al. Avian cell line - Technology for large scale vaccine production. BMC proceedings 2011, 5(Nov 22 (Suppl 8)):P52.
56. Wolff M.W., Siewert C., Hansen S.P., Faber R., Reichl U. Purification of cell culture-derived modified vaccinia ankara virus by pseudo-affinity membrane adsorbers and hydrophobic interaction chromatography. Biotechnol Bioeng 2010 Oct 1, 107(2):312-320.
57. Wolff M.W., Siewert C., Lehmann S., Hansen S.P., Djurup R., Faber R., et al. Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers. Biotechnol Bioeng 2010, 105(March (4)):761-769.
58. Laidlaw S.M., Skinner M.A. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses. J Gen Virol 2004, 85(February (2)):305-322.
59. Bejon P., Mwacharo J., Kai O.K., Todryk S., Keating S., Lang T., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 2006, 24(May (22)):4709-4715.
60. Harrop R., Connolly N., Redchenko I., Valle J., Saunders M., Ryan M.G., et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006, 12(June (11)):3416-3424.
61. Harrop R., John J., Carroll M.W. Recombinant viral vectors: cancer vaccines. Advanced drug delivery reviews 2006, 58(October (8)):931-947.
62. Harrop R., Shingler W., Kelleher M., de Belin J., Treasure P. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother 2010, 33(November-December (9)):999-1005.
63. Moorthy V.S., Imoukhuede E.B., Keating S., Pinder M., Webster D., Skinner M.A., et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004, 189(June (12)):2213-2219.
64. McCurdy L.H., Larkin B.D., Martin J.E., Graham B.S. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 2004, 38(June (12)):1749-1753.
65. Jordan I., Munster V.J., Sandig V. Authentication of the R06E fruit bat cell line. Viruses 2012, 4(May (5)):889-900.
66. Jordan I., Horn D., Oehmke S., Leendertz F.H., Sandig V. Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara. Virus Res 2009, 145(October (1)):54-62.
67. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238(November (2)):198-211.
68. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998, (February (79)):347-352.
69. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998, (May (79)):1159-1167.